赣南医科大学学报2024，Vol.44Issue(11)：1163-1169,7.DOI:10.3969/j.issn.1001-5779.2024.11.013
肿瘤细胞核程序性死亡配体1的研究进展
Progress in the nuclear programmed cell death ligand 1 in nucleus tumor cell
摘要
Abstract
Programmed cell death ligand 1(PD-L1)is a type Ⅰ transmembrane protein that binds to programmed cell death protein 1(PD-1)to induce tumor immune escape.Clinical immunotherapy targeting the PD-1/PD-L1 pathway has been gradually developed.However,satisfactory results have not been achieved in some tumor treatment.Recent studies have found that PD-L1 is not only localized in the cell membrane,but also appears in the cytoplasm,the nucleus,or outside the cell with corresponding functions.This paper summarizes the expression,transport,function,detection and clinical significance of nuclear PD-L1(nPD-L1),based on recent domestic and foreign research literature.The results of literature review show that PD-L1 is expressed in a variety of tumor nuclei.Under the action of external stimuli,PD-L1 can be transported to the nucleus through several signaling pathways such as Karyopherin,signal transducer and activator of transcription 3,protein kinase B,extracellular regulated protein kinases,and regulate the proliferation and death,immunity,blood vessels and stem cell generation of tumor.Detection of the expression of nPD-L1 by immunohistochemistry and other methods is of great significance for the diagnosis,treatment,prognosis,monitoring and follow-up of tumors,and nPD-L1 may become a new therapeutic target and enter clinical application.关键词
程序性死亡配体1/细胞核程序性死亡配体1/组蛋白去乙酰化酶/作用机制Key words
Programmed cell death ligand 1/Nuclear programmed cell death ligand 1/Histone deacetylase/Mechanism of action分类
医药卫生引用本文复制引用
邓晓,邱莎莎..肿瘤细胞核程序性死亡配体1的研究进展[J].赣南医科大学学报,2024,44(11):1163-1169,7.基金项目
江西省教育厅科学技术研究项目(GJJ201513) （GJJ201513）
